(Q73378684)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

K P Wandinger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

K Wessel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

P Neustock

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

A Siekhaus

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

H Kirchner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 July 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

Journal of the Neurological Sciences

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

87-93

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Stimulation of oligodendroglial proliferation and maturation by interleukin-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Myelin basic protein-specific RNA levels in interleukin-2-stimulated oligodendrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

The adhesion molecule and cytokine profile of multiple sclerosis lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Plaque-associated expression of human herpesvirus 6 in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interferon induction, 2'-5' oligo A synthetase and lymphocyte subpopulations in out-patients with multiple sclerosis in a longitudinal study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interleukin-2 enhances chick and rat sympathetic, but not sensory, neurite outgrowth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Human leukocyte antigen studies in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

A whole-blood technique for testing production of human interferon by leukocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

The interferon system as an integral part of the defense system against infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Defective production of interleukin-2 in patients with idiopathic Parkinson's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Defining the clinical course of multiple sclerosis: Results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

New treatments for multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

The multiple sclerosis lesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interleukin-2 effects in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interferon responses of leukocytes in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Molecular cloning of IL-2R alpha, IL-2R beta, and IL-2R gamma cDNAs from a human oligodendroglioma cell line: presence of IL-2R mRNAs in the human central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Influence of infection on exacerbations of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Myelin basic protein-reactive human T-cell clones: stimulation by diverse microbial antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

PPD-, PWM-, and PHA-induced interferon in stable multiple sclerosis: association with HLA-Dw2 antigen and clinical variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interleukin 2 mediates the inhibition of oligodendrocyte progenitor cell proliferation in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interleukin-1 and interleukin-2 production by peripheral blood mononuclear cells in multiple sclerosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Clinical viral infections and multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interleukin-2: inception, impact, and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Interferon production by lymphocytes from multiple sclerosis and non-MS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2897%2905383-5

Affinity chromatography of human leukocyte and diploid cell interferons on sepharose-bound antibodies

7 January 2021

1 reference

12 December 2020

Notes on the pathogenesis of multiple sclerosis.

1 reference

12 December 2020

Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients

1 reference

12 December 2020

Association of human leucocyte low responsiveness to inducers of interferon alpha with HLA-DR 2

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

10.1016/S0022-510X(97)05383-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9168171%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference